Existing Annotations Review

GO Term	Evidence	Action	Reason
GO:0005576 extracellular region	IEA GO_REF:0000044	KEEP AS NON CORE	Summary: Electronic (UniProt SubCell "Secreted") assignment of extracellular localization. TXNDC16 is partly secreted because its KDEL-type ER-retrieval motif is masked and non-functional. This is a real but secondary localization relative to its primary ER-lumen residence. Reason: Secretion is genuine but secondary; the protein's primary site is the ER lumen. Supporting Evidence: file:human/TXNDC16/TXNDC16-uniprot.txt SUBCELLULAR LOCATION: Secreted
GO:0005788 endoplasmic reticulum lumen	IEA GO_REF:0000044	ACCEPT	Summary: Electronic assignment of ER-lumen localization, consistent with the experimental IDA/EXP annotations and the curated subcellular location. This is the primary site of TXNDC16. Reason: Correct primary localization; TXNDC16/ERp90 is a soluble ER-luminal glycoprotein. Supporting Evidence: file:human/TXNDC16/TXNDC16-uniprot.txt Endoplasmic reticulum lumen
GO:0005576 extracellular region	EXP PMID:25122923 Secretion and immunogenicity of the meningioma-associated an...	KEEP AS NON CORE	Summary: Experimental demonstration that TXNDC16 is secreted from human cell lines because its ER retrieval motif is masked and non-functional. A real but secondary localization. Reason: Genuine secretion arising from the masked KDEL motif, but secondary to the primary ER-lumen localization. Supporting Evidence: PMID:25122923 We were able to show TXNDC16 secretion in different human cell lines due to masked and therefore nonfunctional ER retrieval motif.
GO:0005788 endoplasmic reticulum lumen	EXP PMID:25122923 Secretion and immunogenicity of the meningioma-associated an...	ACCEPT	Summary: Experimental confirmation of the ER-luminal glycoprotein localization of TXNDC16. Reason: Correct primary localization, consistent with the IDA and electronic annotations. Supporting Evidence: PMID:25122923 TXNDC16 was previously found to be an endoplasmic reticulum (ER)-luminal glycoprotein.
GO:0005515 protein binding	IPI PMID:21359175 Identification of the PDI-family member ERp90 as an interact...	KEEP AS NON CORE	Summary: Co-immunoprecipitation showing TXNDC16/ERp90 directly interacts with ERFAD (FOXRED2), an ER flavoprotein involved in ERAD. This is the functionally most informative interaction for TXNDC16, suggesting an ERAD substrate-recruitment/delivery role, but the bare protein binding term itself is uninformative. Reason: Records a genuine, functionally meaningful ERAD-related interaction, but per guidelines bare protein binding is not elevated to a core molecular function; a more specific adapter/ERAD term would be preferable if the role is confirmed. Supporting Evidence: PMID:21359175 ERp90 co-immunoprecipitates with ERFAD, a flavoprotein involved in ER-associated degradation (ERAD), through what is most likely a direct interaction.
GO:0005788 endoplasmic reticulum lumen	IDA PMID:21359175 Identification of the PDI-family member ERp90 as an interact...	ACCEPT	Summary: Direct evidence that ERp90/TXNDC16 is a soluble ER-luminal glycoprotein. Reason: Experimentally supported primary localization. Supporting Evidence: PMID:21359175 we find ERp90 to be a soluble ER-luminal glycoprotein that comprises five potential thioredoxin (Trx)-like domains.
GO:0070062 extracellular exosome	HDA PMID:19199708 Proteomic analysis of human parotid gland exosomes by multid...	KEEP AS NON CORE	Summary: High-throughput proteomic detection of TXNDC16 in parotid-gland exosomes. A later study could not confirm exosomal secretion in HEK293 cells, so this localization is uncertain; retained as non-core rather than removed since it is a proteomics-based experimental detection. Reason: Proteomic detection in exosomes that was not reproduced in a subsequent study (PMID:25122923); uncertain and non-core, but not removed on weak grounds. Supporting Evidence: PMID:25122923 A previously indicated exosomal TXNDC16 secretion could not be confirmed in HEK293 cells.

Core Functions

ER-luminal PDI-family glycoprotein that lacks a canonical CXXC redox motif and acts as a direct interaction partner of the ERAD flavoprotein ERFAD (FOXRED2), proposed to function in recruitment or delivery of substrates to the ERAD retrotranslocation machinery.

Cellular Locations:

endoplasmic reticulum lumen

Supporting Evidence:

PMID:21359175
We propose that the function of ERp90 is related to substrate recruitment or delivery to the ERAD retrotranslocation machinery by ERFAD.

References

GO_REF:0000044

Gene Ontology annotation based on UniProtKB/Swiss-Prot Subcellular Location vocabulary mapping, accompanied by conservative changes to GO terms applied by UniProt

PMID:19199708

Proteomic analysis of human parotid gland exosomes by multidimensional protein identification technology (MudPIT).

PMID:21359175

Identification of the PDI-family member ERp90 as an interaction partner of ERFAD.

ERp90/TXNDC16 is a soluble ER-luminal glycoprotein with about five potential thioredoxin domains, none of which contain a canonical CXXC active-site motif; it directly interacts with the ERAD flavoprotein ERFAD (FOXRED2), suggesting a role in substrate recruitment/delivery to the ERAD retrotranslocation machinery.

PMID:25122923

Secretion and immunogenicity of the meningioma-associated antigen TXNDC16.

TXNDC16 is an ER-luminal glycoprotein that is secreted from human cell lines because its KDEL ER-retrieval motif is masked and non-functional; it is a meningioma-associated antigen, and a previously reported exosomal secretion could not be confirmed.

PMID:32971745

Oxidoreductases in Glycoprotein Glycosylation, Folding, and ERAD.

Authoritative review that classifies ERp90/TXNDC16 as a non-catalytic PDI-family member whose thioredoxin-like domains carry non-canonical motifs (CX8C, CX9C, CX6C) rather than active CXXC, and places it within the ERAD retrotranslocation network alongside factors such as OS-9 and SEL1L.

PMID:38673779

Innovation in Non-Invasive Diagnosis and Disease Monitoring for Meningiomas.

Review of meningioma liquid-biopsy approaches that summarizes prior work on TXNDC16 as a meningioma-associated antigen, noting a five-epitope autoantibody panel discriminating meningioma from healthy sera with ~90% sensitivity and ~83.7% specificity as a proof-of-concept serology biomarker.

file:human/TXNDC16/TXNDC16-uniprot.txt

UniProt entry Q9P2K2 (TXD16_HUMAN), Thioredoxin domain-containing protein 16

Large PDI-family ER-luminal glycoprotein (ERp90) with a thioredoxin domain and a masked, non-functional KDEL ER-retention motif; interacts with FOXRED2 (ERFAD); secreted.

Suggested Experiments

Experiment: Knock out TXNDC16 in human cells and assay the degradation kinetics of model ERAD substrates, with and without ERFAD/FOXRED2, to test the proposed substrate-delivery function.

Experiment: Perform in vitro redox assays (e.g., insulin turbidimetric reduction, RNase refolding) with purified TXNDC16 and active-site cysteine mutants to determine whether it has any catalytic oxidoreductase activity in the absence of a canonical CXXC motif.

Knowledge Gaps

What is not known — curated, literature-grounded statements of the open unknowns (the inverse of core functions).

Gap: It is unresolved whether TXNDC16/ERp90 is a purely non-catalytic PDI-family scaffold/adaptor or whether it performs a CXXC-independent redox activity using conserved noncanonical cysteines.

OPEN BIOLOGYONTOLOGY MF_DARK

What is known: ERp90 is a soluble ER-luminal PDI-family glycoprotein with five Trx-like domains and no canonical Cys-Xaa-Xaa-Cys active-site motif; some cysteines form intramolecular disulfides. The open question is whether those noncanonical cysteines are structural only or contribute directly to redox chemistry.

Significance: The molecular function cannot be curated more specifically than ER-lumen localization and ERFAD binding until this distinction is resolved; a catalytic oxidoreductase role and a non-catalytic substrate-adaptor role imply different GO molecular functions.

What would resolve it: Purify full-length ERp90 and cysteine mutants for redox assays, disulfide-state mapping, and ERFAD-dependent substrate handoff assays in parallel with cellular rescue experiments.

Provenance (the field's own admissions):

"While none of the Trx domains contain a canonical Cys-Xaa-Xaa-Cys active-site motif, other conserved cysteines could endow the protein with redox activity." — PMID:21359175
"Finally, ERp90 could perform a CXXC-independent redox function, conceivably in collaboration with the redox-active ERFAD, through the conserved C664 or even the CX9C motif in the Trx2." — PMID:21359175

Gap: The ERAD substrate set and pathway step that depend on TXNDC16 remain unknown. ERp90 is proposed to help ERFAD recruit or deliver substrates to the retrotranslocation machinery, but no endogenous substrates or loss-of-function ERAD defects have been demonstrated.

OPEN BIOLOGY BP_DARK

What is known: TXNDC16/ERp90 physically associates with ERFAD/FOXRED2 and is positioned in the ERAD luminal network. What is missing is functional evidence that specific glycoprotein or disulfide-containing ERAD clients require TXNDC16 for recognition, reduction, handoff to SEL1L/OS-9, retrotranslocation, or degradation.

Significance: This gap separates an interaction-based ERAD hypothesis from a process annotation. Resolving it would define whether TXNDC16 is a core ERAD factor, a client-specific cofactor, or a bystander in an ERFAD-containing complex.

What would resolve it: Generate TXNDC16 knockout/rescue cells and measure degradation, disulfide status, and retrotranslocation of model and proteome-wide ERAD substrates, including ERFAD-dependent and ERFAD-independent contexts.

Provenance (the field's own admissions):

"Since we did not succeed in performing siRNA-mediated knockdown experiments of ERp90 to study an involvement of ERp90 in ERAD, we can presently only speculate about the function of ERp90 in relation to ERFAD." — PMID:21359175
"Future work should allow us to distinguish between these various possibilities." — PMID:21359175

Gap: The biological significance of TXNDC16 secretion and meningioma-associated autoantibodies is unclear. TXNDC16 is secreted because its ER-retrieval motif is masked, and antibodies can distinguish meningioma sera, but it is not known whether extracellular TXNDC16 has a function or is mainly a biomarker/immunogenic byproduct of leakage from the ER-lumen pool.

OPEN BIOLOGYCURATION RESIDUAL_SUBGAP

What is known: Secretion from multiple human cell lines and circulating immune complexes are documented, while exosomal secretion was not confirmed in HEK293 cells. The unresolved part is whether secreted TXNDC16 participates in disease biology, antigen presentation, or immune-complex formation beyond diagnostic association.

Significance: This limits curation of extracellular annotations: secretion is real and should be retained, but disease-associated immunogenicity should not be interpreted as a normal extracellular molecular function without mechanistic evidence.

What would resolve it: Determine the source and form of serum TXNDC16 in meningioma and controls, test whether immune complexes contain intact secreted protein or fragments, and assess any extracellular effects on immune or tumor cells.

Provenance (the field's own admissions):

"We were able to show TXNDC16 secretion in different human cell lines due to masked and therefore nonfunctional ER retrieval motif." — PMID:25122923
"The secreted serum protein TXNDC16 is bound in circulating immune complexes, which were found both in meningioma and healthy blood donor sera." — PMID:25122923
"A previously indicated exosomal TXNDC16 secretion could not be confirmed in HEK293 cells." — PMID:25122923

Deep Research

Falcon

(TXNDC16-deep-research-falcon.md)

this with annotations you find in gene/protein databases, but these can be outdated or inaccurate. Falcon Edison Scientific Literature 20 citations 2 artifacts 2026-06-12T04:41:46.764150

Edison artifact artifact-00 (text/markdown)

## Context ID: pqac-00000016 Figure 1 on page 5 shows the ER localization of TXNDC16 and its colocalization with the ER-luminal protein PDI (Panel A). Figure 2 (image/png)

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Research report: Human TXNDC16 (ERp90; UniProt Q9P2K2)—functional annotation, localization, pathways, and translational relevance

0) Target verification (mandatory)

The literature retrieved here is consistent with the requested target: human TXNDC16 (thioredoxin domain-containing protein 16), also referred to as ERp90, and described as an ER-luminal glycoprotein with ER-targeting/retention features. This matches the UniProt-provided identity and the stated thioredoxin-like domain architecture. (harz2014secretionandimmunogenicity pages 1-2, oliveira2025endoplasmicreticulumredoxome pages 4-5)

1) Key concepts and definitions (current understanding)

1.1 Thioredoxin-like / PDI-family-like proteins in the ER

Proteins with thioredoxin-like domains in the endoplasmic reticulum (ER) often participate in oxidative protein folding, quality control, and ER-associated degradation (ERAD). Many have catalytic CXXC active-site motifs to mediate thiol–disulfide exchange; however, some members are non-catalytic, functioning as scaffolds/adaptors within folding/ERAD complexes rather than directly catalyzing disulfide chemistry. TXNDC16 is repeatedly placed in this ER oxidoreductase/quality-control context. (oliveira2025endoplasmicreticulumredoxome pages 4-5, patel2020oxidoreductasesinglycoprotein pages 7-9)

1.2 ER targeting and retention/retrieval signals

Secretory-pathway proteins are typically targeted to the ER by an N-terminal signal peptide, enabling cotranslational ER translocation via SRP/Sec61 and signal-peptidase cleavage. ER luminal resident proteins commonly use C-terminal KDEL-like motifs for retrieval from the Golgi back to the ER, though these signals can be context-dependent or functionally masked. TXNDC16 includes a predicted signal peptide and a KDEL-variant (DKEL), but its retention can be incomplete. (harz2014secretionandimmunogenicity pages 2-3, harz2014secretionandimmunogenicity pages 6-6)

2) Molecular identity, domain architecture, and biochemical function

2.1 Protein identity and size

TXNDC16 was described as having a molecular mass of ~93 kDa (reference sequence cited in the primary paper) and being broadly expressed across normal and many cancer tissues. (harz2014secretionandimmunogenicity pages 1-2)

2.2 Domain/motif-level functional inference: “thioredoxin-like but non-catalytic”

A key point for functional annotation is that TXNDC16/ERp90 contains multiple thioredoxin-like domains but is annotated in an authoritative ER folding/ERAD review as having inactive/non-canonical Trx-like motifs (e.g., CX8C, CX9C, CX6C rather than canonical catalytic CXXC). This is presented as evidence that ERp90 is non-catalytic (i.e., not a classical thiol–disulfide oxidoreductase enzyme), supporting a role as a structural/complex component in ER quality control rather than a substrate-specific oxidoreductase. (patel2020oxidoreductasesinglycoprotein pages 5-7, patel2020oxidoreductasesinglycoprotein pages 7-9)

Implication for “primary function” request: based on the retrieved sources, TXNDC16 is best described as a PDI/thioredoxin-domain-containing ER quality-control factor without a clearly defined catalytic reaction or specific substrate list; its functional evidence is stronger at the pathway/complex level (ERAD association) than at the substrate-specific enzymology level. (patel2020oxidoreductasesinglycoprotein pages 7-9, patel2020oxidoreductasesinglycoprotein pages 5-7)

3) Subcellular localization and trafficking

3.1 ER localization (experimental evidence)

Harz et al. (2014, J Immunol, published online Aug 13, 2014; issue Sep 2014; https://doi.org/10.4049/jimmunol.1303098) performed confocal microscopy in human cells expressing TXNDC16-HA and reported colocalization with PDI, an ER-luminal marker, supporting ER localization. Deleting the first 27 amino acids (the predicted signal peptide) shifted localization from ER-associated to cytosolic, showing the signal peptide is required for ER targeting. (harz2014secretionandimmunogenicity pages 3-4)

Visual evidence for ER localization and domain schematic is present in the paper’s figures. (harz2014secretionandimmunogenicity media 3c06b519, harz2014secretionandimmunogenicity media d160178d)

3.2 ER retention vs secretion (unusual behavior)

Despite harboring a KDEL-like motif (DKEL), Harz et al. report that TXNDC16 can be secreted into supernatants from multiple human cell lines, and they interpret this as being due to a masked/nonfunctional ER retrieval motif (i.e., incomplete ER retention). They further report detection of TXNDC16 protein in serum, bound in circulating immune complexes, and discuss uncertainty regarding whether secretion is classical ER/Golgi-dependent or unconventional. They did not confirm a previously suggested exosomal secretion mechanism in HEK293 cells (CD63-marked fraction). (harz2014secretionandimmunogenicity pages 1-2, harz2014secretionandimmunogenicity pages 6-6, harz2014secretionandimmunogenicity pages 8-8)

4) Pathways and interaction partners (ERAD-focused)

4.1 ERAD/retrotranslocation complexes

In a widely cited review on oxidoreductases in glycoprotein folding and ERAD (Patel et al., 2020, Cells, Sep 2020; https://doi.org/10.3390/cells9092138), TXNDC16 (ERp90) is specifically placed in the ERAD (retrotranslocation) category and described as non-catalytic. The review reports interactions/associations with the ERAD lectin OS-9 and adaptor SEL1L, and positions ERp90 in assemblies alongside other ERAD redox/processing factors (e.g., ERdj5; ERFAD noted as NADPH-dependent reductase). This supports a model where TXNDC16 acts as a component of ERAD machinery—likely in recognition/scaffolding or organization of ERAD complexes—rather than directly performing thiol–disulfide catalysis. (patel2020oxidoreductasesinglycoprotein pages 5-7, patel2020oxidoreductasesinglycoprotein pages 7-9)

4.2 Expert framing within the “ER redoxome”

A more recent review of the ER redoxome includes TXNDC16 among PDI/thioredoxin-domain-containing proteins (alias ERp90), reinforcing its placement within ER proteostasis/redox networks, while not adding TXNDC16-specific mechanistic detail in the excerpt retrieved. (oliveira2025endoplasmicreticulumredoxome pages 4-5)

5) Recent developments and latest research (prioritizing 2023–2024)

5.1 2024 expert review: TXNDC16 in non-invasive meningioma biomarker development

Korte & Mathios (2024, International Journal of Molecular Sciences, Apr 2024; https://doi.org/10.3390/ijms25084195) review liquid biopsy approaches for meningioma and summarize prior TXNDC16 work as a meningioma-associated antigen. They cite evidence that a panel of five TXNDC16 immunogenic epitopes (derived from mapping 163 overlapping peptides) could discriminate meningioma from healthy sera with ~90% sensitivity and ~83.7% specificity, framing this as a proof-of-concept serology/autoantibody liquid biopsy approach. They also provide expert cautions that tumor-associated antigen (TAA) autoantibodies can lack specificity across cancers or occur in autoimmunity/healthy individuals, implying that TXNDC16 would likely perform best as part of multi-antigen panels and within well-validated clinical workflows. (korte2024innovationinnoninvasive pages 7-9)

5.2 2023–2024 TXNDC16 mechanistic biology: limited direct primary data retrieved

Within the retrieved 2023–2024 corpus, TXNDC16 appears mainly in review/omics contexts rather than in detailed mechanistic papers focused on TXNDC16. A 2024 PNAS study in mouse testis proteomics (in the context of multi-gene knockout in the WFDC cluster) notes TXNDC16 upregulation among proteins associated with protein degradation/quality control, which is directionally consistent with an ER quality-control role but is not TXNDC16-specific mechanistic proof in human cells. (kent2024largescalecrisprcas9deletions pages 8-9)

6) Current applications and real-world implementations

6.1 Potential clinical application: serology-based meningioma liquid biopsy (not yet clinically validated)

The most concrete translational “implementation pathway” is serum-based detection of anti-TXNDC16 autoantibodies using peptide arrays or reduced epitope panels. This is supported by primary serology results (Harz et al. 2014) and positioned within the broader liquid biopsy landscape in a 2024 review, but remains a proof-of-concept rather than an approved clinical test. (harz2014secretionandimmunogenicity pages 6-7, korte2024innovationinnoninvasive pages 7-9)

6.2 Systems/proteostasis application: inclusion in ERAD network models

In cell biology and proteostasis research, TXNDC16/ERp90 is used as a named component of the ERAD retrotranslocation network (OS-9/SEL1L-associated), which can guide experimental design (e.g., ERAD complex mapping, perturbation studies of ER proteostasis). This is a “real-world” research application as part of ERAD conceptual/interaction maps. (patel2020oxidoreductasesinglycoprotein pages 7-9)

7) Expert opinions and analysis (authoritative synthesis)

Non-catalytic classification: Patel et al. (2020) explicitly characterize ERp90/TXNDC16 as non-catalytic, with inactive Trx-like motifs and placement in ERAD complexes with OS-9 and SEL1L; this constitutes a strong expert synthesis for functional inference in the absence of substrate-level enzymology. (patel2020oxidoreductasesinglycoprotein pages 7-9, patel2020oxidoreductasesinglycoprotein pages 5-7)
Biomarker caution: Korte & Mathios (2024) highlight the promise of autoantibody-based detection but emphasize practical limitations (heterogeneity, cross-reactivity, and need for validation/panels), which is critical for interpreting TXNDC16 biomarker potential. (korte2024innovationinnoninvasive pages 7-9)

8) Statistics and quantitative data from studies

8.1 Meningioma discrimination performance (primary data)

Harz et al. (2014, J Immunol; https://doi.org/10.4049/jimmunol.1303098) report that while no single TXNDC16 epitope was universally recognized, a five-epitope subset chosen from a 163-peptide overlapping array discriminated meningioma vs controls with ~87.2% accuracy, ~90% sensitivity, and ~83.7% specificity; using all peptides yielded substantially worse performance (~53.8% accuracy, ~24.2% specificity, ~77.3% sensitivity). These values are restated in the 2024 review as evidence supporting TXNDC16’s biomarker potential. (harz2014secretionandimmunogenicity pages 6-7, korte2024innovationinnoninvasive pages 7-9)

8.2 Database-level disease association scores (interpret with caution)

Open Targets returns low association scores for TXNDC16 with several diseases (including meningioma and Alzheimer disease), but with zero underlying evidence rows in the retrieved output. These associations therefore should not be treated as strong evidence of causality or clinical utility without supporting primary genetics/functional studies. (OpenTargets Search: -TXNDC16)

9) Limitations and evidence gaps (important for functional annotation)

Substrate/client specificity: No retrieved primary study here defines specific substrates (“client proteins”) of TXNDC16 or a catalytic reaction with substrate specificity, consistent with its classification as non-catalytic in ERAD contexts. (patel2020oxidoreductasesinglycoprotein pages 7-9, patel2020oxidoreductasesinglycoprotein pages 5-7)
Mechanistic depth in 2023–2024: The most TXNDC16-relevant 2024 source retrieved is a review (meningioma liquid biopsy). More recent TXNDC16-centered mechanistic studies may exist but were not surfaced in the current retrieval results. (korte2024innovationinnoninvasive pages 7-9)
Secretion biology unresolved: TXNDC16 shows atypical retention/secretion behavior; the secretion route (classical vs unconventional) is not resolved in the primary study and likely depends on cell type and protein context. (harz2014secretionandimmunogenicity pages 8-8)

Summary table of evidence

Aspect	Finding	Best supporting citations
Identity/synonyms	TXNDC16 is the human gene matching UniProt Q9P2K2; reported synonyms include ERp90 and KIAA1344. Harz 2014 identifies TXNDC16 as a meningioma-associated antigen and notes it had previously been characterized as an ER-luminal glycoprotein. Harz 2014, J Immunol, published Sep 2014, URL: https://doi.org/10.4049/jimmunol.1303098	(harz2014secretionandimmunogenicity pages 1-2)
Domains/motifs	TXNDC16/ERp90 is a thioredoxin domain-containing, PDI-family-like protein. Review evidence places it in the ER oxidoreductase network but notes its Trx-like motifs are non-canonical/inactive rather than classical catalytic CXXC motifs: Trxl1-CX8C, Trxl2-CX9C, Trxl3-CX6C, Trxl4/5 inactive. It also has a predicted N-terminal 27 aa signal peptide and a C-terminal DKEL KDEL-like motif. Patel 2020, Cells, Sep 2020, URL: https://doi.org/10.3390/cells9092138	(patel2020oxidoreductasesinglycoprotein pages 5-7, harz2014secretionandimmunogenicity pages 2-3, harz2014secretionandimmunogenicity media 3c06b519)
Subcellular localization	Experimental data support predominant ER luminal/ER-associated localization. TXNDC16-HA colocalizes with PDI by confocal microscopy, and deleting the signal peptide shifts localization from ER-associated to cytosolic, showing signal-peptide-dependent ER targeting. Harz 2014, J Immunol, Sep 2014, URL: https://doi.org/10.4049/jimmunol.1303098	(harz2014secretionandimmunogenicity pages 3-4, harz2014secretionandimmunogenicity media 3c06b519)
Secretion/extracellular presence	Despite ER-targeting features, TXNDC16 is also reported in cell-culture supernatants and serum/circulating immune complexes. Harz 2014 concluded secretion likely reflects a masked/nonfunctional ER retrieval motif; the authors could not confirm prior exosomal secretion in HEK293 cells. Korte 2024 highlights this as a basis for liquid-biopsy interest. Korte 2024, Int J Mol Sci, Apr 2024, URL: https://doi.org/10.3390/ijms25084195	(harz2014secretionandimmunogenicity pages 1-2, harz2014secretionandimmunogenicity pages 6-6, harz2014secretionandimmunogenicity pages 8-8, korte2024innovationinnoninvasive pages 7-9, harz2014secretionandimmunogenicity pages 6-7)
Proposed molecular function	Current evidence supports TXNDC16 as an ER quality-control/thioredoxin-like scaffold or chaperone-associated factor, not a well-established classical oxidoreductase enzyme. Because its Trx-like domains lack canonical catalytic motifs, the strongest inference is a role in ER protein folding/quality control and ERAD-associated processes, rather than a defined substrate-specific disulfide isomerase reaction. Patel 2020, Cells, Sep 2020, URL: https://doi.org/10.3390/cells9092138	(patel2020oxidoreductasesinglycoprotein pages 5-7, oliveira2025endoplasmicreticulumredoxome pages 4-5)
Interactions/complexes	TXNDC16/ERp90 is specifically linked to ERAD retrotranslocation machinery, with reported interactions involving OS-9 and SEL1L in review summaries of ER glycoprotein quality control. This places TXNDC16 in pathways handling misfolded glycoproteins in the ER. Patel 2020, Cells, Sep 2020, URL: https://doi.org/10.3390/cells9092138	(patel2020oxidoreductasesinglycoprotein pages 5-7)
Disease/biomarker evidence	The clearest disease-relevant evidence is in meningioma serology. TXNDC16 was identified as a meningioma-associated antigen with autoantibody reactivity; Korte 2024 reviews it as a proof-of-concept liquid biopsy biomarker based on serum autoantibodies/peptide arrays. Open Targets currently lists only very weak association scores with zero underlying evidence rows for diseases including meningioma, Alzheimer disease, chronic kidney disease, eye disease, and tinnitus, so these database associations should be treated cautiously. Open Targets query context available in this session.	(korte2024innovationinnoninvasive pages 7-9, harz2014secretionandimmunogenicity pages 6-7, OpenTargets Search: -TXNDC16)
Key statistics	Harz 2014 reports TXNDC16 has a ~93 kDa predicted molecular mass and that a 5-epitope panel derived from 163 overlapping peptides discriminated meningioma vs controls with 87.2% accuracy, 90% sensitivity, and 83.7% specificity; using all peptides performed much worse (53.8% accuracy, 24.2% specificity, 77.3% sensitivity). Korte 2024 reiterates the approximate 90% sensitivity / 83.7% specificity result as support for non-invasive biomarker development. Harz 2014, J Immunol, Sep 2014, URL: https://doi.org/10.4049/jimmunol.1303098; Korte 2024, Int J Mol Sci, Apr 2024, URL: https://doi.org/10.3390/ijms25084195	(harz2014secretionandimmunogenicity pages 1-2, korte2024innovationinnoninvasive pages 7-9, harz2014secretionandimmunogenicity pages 6-7)

Table: This table summarizes the strongest available functional annotation evidence for human TXNDC16/ERp90, including identity verification, ER localization, inferred molecular role, ERAD associations, and current biomarker evidence. It is useful for distinguishing well-supported findings from weaker database-level disease associations.

Key sources (with dates and URLs)

Harz C. et al. “Secretion and Immunogenicity of the Meningioma-Associated Antigen TXNDC16.” The Journal of Immunology (prepublished online 13 Aug 2014; issue Sep 2014). https://doi.org/10.4049/jimmunol.1303098 (harz2014secretionandimmunogenicity pages 1-2)
Patel C. et al. “Oxidoreductases in Glycoprotein Glycosylation, Folding, and ERAD.” Cells (Sep 2020). https://doi.org/10.3390/cells9092138 (patel2020oxidoreductasesinglycoprotein pages 5-7)
Korte B., Mathios D. “Innovation in Non-Invasive Diagnosis and Disease Monitoring for Meningiomas.” International Journal of Molecular Sciences (Apr 2024). https://doi.org/10.3390/ijms25084195 (korte2024innovationinnoninvasive pages 7-9)
Open Targets Platform: TXNDC16 disease associations (query output in this session; evidence rows absent). https://platform.opentargets.org/ (OpenTargets Search: -TXNDC16)

References

(harz2014secretionandimmunogenicity pages 1-2): Christian Harz, Nicole Ludwig, Sven Lang, Tamara V. Werner, Valentina Galata, Christina Backes, Katja Schmitt, Ruth Nickels, Elmar Krause, Martin Jung, Jens Rettig, Andreas Keller, Michael Menger, Richard Zimmermann, and Eckart Meese. Secretion and immunogenicity of the meningioma-associated antigen txndc16. The Journal of Immunology, 193:3146-3154, Sep 2014. URL: https://doi.org/10.4049/jimmunol.1303098, doi:10.4049/jimmunol.1303098. This article has 10 citations.
(oliveira2025endoplasmicreticulumredoxome pages 4-5): Percillia V. S. Oliveira, Tiphany C. De Bessa, and Francisco R. M. Laurindo. Endoplasmic reticulum redoxome: protein folding and beyond. Biochemistry, 65(1):1-30, Dec 2025. URL: https://doi.org/10.1021/acs.biochem.5c00527, doi:10.1021/acs.biochem.5c00527. This article has 7 citations and is from a peer-reviewed journal.
(patel2020oxidoreductasesinglycoprotein pages 7-9): Chaitanya Patel, Haddas Saad, Marina Shenkman, and Gerardo Z. Lederkremer. Oxidoreductases in glycoprotein glycosylation, folding, and erad. Sep 2020. URL: https://doi.org/10.3390/cells9092138, doi:10.3390/cells9092138. This article has 33 citations.
(harz2014secretionandimmunogenicity pages 2-3): Christian Harz, Nicole Ludwig, Sven Lang, Tamara V. Werner, Valentina Galata, Christina Backes, Katja Schmitt, Ruth Nickels, Elmar Krause, Martin Jung, Jens Rettig, Andreas Keller, Michael Menger, Richard Zimmermann, and Eckart Meese. Secretion and immunogenicity of the meningioma-associated antigen txndc16. The Journal of Immunology, 193:3146-3154, Sep 2014. URL: https://doi.org/10.4049/jimmunol.1303098, doi:10.4049/jimmunol.1303098. This article has 10 citations.
(harz2014secretionandimmunogenicity pages 6-6): Christian Harz, Nicole Ludwig, Sven Lang, Tamara V. Werner, Valentina Galata, Christina Backes, Katja Schmitt, Ruth Nickels, Elmar Krause, Martin Jung, Jens Rettig, Andreas Keller, Michael Menger, Richard Zimmermann, and Eckart Meese. Secretion and immunogenicity of the meningioma-associated antigen txndc16. The Journal of Immunology, 193:3146-3154, Sep 2014. URL: https://doi.org/10.4049/jimmunol.1303098, doi:10.4049/jimmunol.1303098. This article has 10 citations.
(patel2020oxidoreductasesinglycoprotein pages 5-7): Chaitanya Patel, Haddas Saad, Marina Shenkman, and Gerardo Z. Lederkremer. Oxidoreductases in glycoprotein glycosylation, folding, and erad. Sep 2020. URL: https://doi.org/10.3390/cells9092138, doi:10.3390/cells9092138. This article has 33 citations.
(harz2014secretionandimmunogenicity pages 3-4): Christian Harz, Nicole Ludwig, Sven Lang, Tamara V. Werner, Valentina Galata, Christina Backes, Katja Schmitt, Ruth Nickels, Elmar Krause, Martin Jung, Jens Rettig, Andreas Keller, Michael Menger, Richard Zimmermann, and Eckart Meese. Secretion and immunogenicity of the meningioma-associated antigen txndc16. The Journal of Immunology, 193:3146-3154, Sep 2014. URL: https://doi.org/10.4049/jimmunol.1303098, doi:10.4049/jimmunol.1303098. This article has 10 citations.
(harz2014secretionandimmunogenicity media 3c06b519): Christian Harz, Nicole Ludwig, Sven Lang, Tamara V. Werner, Valentina Galata, Christina Backes, Katja Schmitt, Ruth Nickels, Elmar Krause, Martin Jung, Jens Rettig, Andreas Keller, Michael Menger, Richard Zimmermann, and Eckart Meese. Secretion and immunogenicity of the meningioma-associated antigen txndc16. The Journal of Immunology, 193:3146-3154, Sep 2014. URL: https://doi.org/10.4049/jimmunol.1303098, doi:10.4049/jimmunol.1303098. This article has 10 citations.
(harz2014secretionandimmunogenicity media d160178d): Christian Harz, Nicole Ludwig, Sven Lang, Tamara V. Werner, Valentina Galata, Christina Backes, Katja Schmitt, Ruth Nickels, Elmar Krause, Martin Jung, Jens Rettig, Andreas Keller, Michael Menger, Richard Zimmermann, and Eckart Meese. Secretion and immunogenicity of the meningioma-associated antigen txndc16. The Journal of Immunology, 193:3146-3154, Sep 2014. URL: https://doi.org/10.4049/jimmunol.1303098, doi:10.4049/jimmunol.1303098. This article has 10 citations.
(harz2014secretionandimmunogenicity pages 8-8): Christian Harz, Nicole Ludwig, Sven Lang, Tamara V. Werner, Valentina Galata, Christina Backes, Katja Schmitt, Ruth Nickels, Elmar Krause, Martin Jung, Jens Rettig, Andreas Keller, Michael Menger, Richard Zimmermann, and Eckart Meese. Secretion and immunogenicity of the meningioma-associated antigen txndc16. The Journal of Immunology, 193:3146-3154, Sep 2014. URL: https://doi.org/10.4049/jimmunol.1303098, doi:10.4049/jimmunol.1303098. This article has 10 citations.
(korte2024innovationinnoninvasive pages 7-9): Brianna Korte and Dimitrios Mathios. Innovation in non-invasive diagnosis and disease monitoring for meningiomas. International Journal of Molecular Sciences, 25:4195, Apr 2024. URL: https://doi.org/10.3390/ijms25084195, doi:10.3390/ijms25084195. This article has 11 citations.
(kent2024largescalecrisprcas9deletions pages 8-9): Katarzyna Kent, Kaori Nozawa, Rachel Parkes, Laura Dean, Frey Daniel, Mei Leng, Antrix Jain, Anna Malovannaya, Martin M. Matzuk, and Thomas X. Garcia. Large-scale crispr/cas9 deletions within the wfdc gene cluster uncover gene functionality and critical roles in mammalian reproduction. Proceedings of the National Academy of Sciences of the United States of America, Dec 2024. URL: https://doi.org/10.1073/pnas.2413195121, doi:10.1073/pnas.2413195121. This article has 10 citations and is from a highest quality peer-reviewed journal.
(harz2014secretionandimmunogenicity pages 6-7): Christian Harz, Nicole Ludwig, Sven Lang, Tamara V. Werner, Valentina Galata, Christina Backes, Katja Schmitt, Ruth Nickels, Elmar Krause, Martin Jung, Jens Rettig, Andreas Keller, Michael Menger, Richard Zimmermann, and Eckart Meese. Secretion and immunogenicity of the meningioma-associated antigen txndc16. The Journal of Immunology, 193:3146-3154, Sep 2014. URL: https://doi.org/10.4049/jimmunol.1303098, doi:10.4049/jimmunol.1303098. This article has 10 citations.
(OpenTargets Search: -TXNDC16): Open Targets Query (-TXNDC16, 5 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

Artifacts

Edison artifact artifact-00

Citations

harz2014secretionandimmunogenicity pages 1-2
harz2014secretionandimmunogenicity pages 3-4
oliveira2025endoplasmicreticulumredoxome pages 4-5
korte2024innovationinnoninvasive pages 7-9
patel2020oxidoreductasesinglycoprotein pages 7-9
harz2014secretionandimmunogenicity pages 8-8
patel2020oxidoreductasesinglycoprotein pages 5-7
harz2014secretionandimmunogenicity pages 2-3
harz2014secretionandimmunogenicity pages 6-6
harz2014secretionandimmunogenicity pages 6-7
https://doi.org/10.4049/jimmunol.1303098
https://doi.org/10.3390/cells9092138
https://doi.org/10.3390/ijms25084195
https://doi.org/10.4049/jimmunol.1303098;
https://platform.opentargets.org/
https://doi.org/10.4049/jimmunol.1303098,
https://doi.org/10.1021/acs.biochem.5c00527,
https://doi.org/10.3390/cells9092138,
https://doi.org/10.3390/ijms25084195,
https://doi.org/10.1073/pnas.2413195121,

TXNDC16/ERp90: Catalytic PDI-Family Oxidoreductase or Non-Catalytic ER-Luminal Scaffold?

(TXNDC16-hypotheses/kgap-txndc16-redox-vs-scaffold/openscientist.md)

citations file

TXNDC16/ERp90: Catalytic PDI-Family Oxidoreductase or Non-Catalytic ER-Luminal Scaffold?

Summary

TXNDC16/ERp90 is a non-catalytic ER-luminal scaffold/adaptor protein, not a catalytic oxidoreductase. Despite belonging to the protein disulfide isomerase (PDI) superfamily by virtue of its multiple thioredoxin-like folds, human TXNDC16 (UniProt Q9P2K2, 825 amino acids) completely lacks the canonical CXXC active-site motifs that are the hallmark of catalytically active PDI-family members. Its ten mature cysteines are arranged in spacings (CX6C, CX8C) incompatible with thioredoxin-fold redox catalysis, and its only annotated disulfide bond (C449–C456) has structural rather than catalytic character. No purified-protein redox assay, cysteine-to-serine mutagenesis study, disulfide-state trapping experiment, or in vitro enzymatic characterization has been published in the 15 years since the protein was first described.

The functional evidence that does exist positions TXNDC16 squarely in the ER-associated degradation (ERAD) pathway as a substrate recruiter. Its co-immunoprecipitation with ERFAD — a luminal flavoprotein that itself interacts with the ERAD machinery components SEL1L, OS-9, and the catalytic reductase ERdj5 — indicates a hand-off role in which TXNDC16 captures or presents misfolded substrates for delivery to the retrotranslocation complex. The original characterizing paper explicitly proposed this model, stating that "the function of ERp90 is related to substrate recruitment or delivery to the ERAD retrotranslocation machinery by ERFAD" (PMID: 21359175).

Based on the totality of available evidence — sequence analysis, domain architecture, absence of catalytic motifs, interaction data, and the complete absence of direct enzymatic evidence — the only defensible Gene Ontology molecular function annotation for TXNDC16 is protein binding (GO:0005515) in the context of ERAD substrate recruitment. Annotation as an oxidoreductase (GO:0016491), protein disulfide isomerase (GO:0003756), or disulfide oxidoreductase (GO:0015036) is not supported by any direct experimental evidence and would constitute unjustified inference from family membership alone.

Key Findings

Finding 1: TXNDC16 Completely Lacks Canonical CXXC Active-Site Motifs

The defining feature of catalytically active PDI-family members is the CXXC motif — two cysteines separated by exactly two intervening residues — located at the N-terminus of an alpha-helix within the thioredoxin fold. This motif enables the reversible formation of a disulfide bond whose reduction potential is tuned by the intervening residues, allowing the protein to catalyze oxidation, reduction, or isomerization of substrate disulfides.

Systematic computational analysis of the full human TXNDC16 sequence (Q9P2K2, 825 amino acids) reveals 10 cysteine residues in the mature protein at positions C51, C84, C93, C216, C226, C449, C456, C664, C767, and C821. Exhaustive regex searches for CXC, CXXC, and CXXXC motifs returned zero matches. The closest cysteine pairs are C84–C93 (CX8C spacing, with 8 intervening residues) and C449–C456 (CX6C spacing, with 6 intervening residues). Both spacings are far wider than the CXXC pattern required for thioredoxin-fold catalysis.

This absence is conserved across evolution: the mouse ortholog (UniProt Q7TN22) also completely lacks CXXC motifs, as do the zebrafish, cow, and rat orthologs. The original characterization by Riemer et al. (2011) explicitly acknowledged this, noting: "While none of the Trx domains contain a canonical Cys-Xaa-Xaa-Cys active-site motif, other conserved cysteines could endow the protein with redox activity" (PMID: 21359175). Crucially, this speculative suggestion was never experimentally tested — by the original authors or by anyone subsequently.

The significance of CXXC absence cannot be overstated. The extensive literature on PDI-family catalysis demonstrates that the CXXC motif is not merely a conserved sequence feature but a mechanistic requirement. Studies on yeast PDI showed that mutation of the CXXC active sites to SGAS abolished catalytic function (PMID: 9298979), and work on the CXXC motif in thioredoxin demonstrated that an enzymatic thiolate with appropriate reduction potential is "both necessary and sufficient for the formation of native disulfide bonds in the cell" (PMID: 8654363). The crystal structure of a CXXC-containing thioredoxin variant (CVWC) confirmed that the motif's geometry directly tunes reduction potential through modulation of the N-terminal cysteine pKa (PMID: 10489448).

{{figure:txndc16_domain_analysis.png|caption=Domain architecture comparison of TXNDC16/ERp90 versus canonical PDI-family members. TXNDC16 contains five thioredoxin-like domains but none harbor the CXXC active-site motif required for catalytic redox activity. Cysteine positions and spacings are shown, highlighting the absence of any catalytically competent motif.}}

Finding 2: The C449–C456 Disulfide Is Structural, Not Catalytic

UniProt annotates a disulfide bond between C449 and C456, based on evidence from the original characterization (PMID: 21359175). The motif is CADWSDVC — a CX6C pattern with six intervening residues. This spacing is conserved in the mouse ortholog (CADWSDIC).

Canonical catalytic CXXC disulfides are solvent-exposed at the end of an alpha-helix within the thioredoxin fold, where they undergo reversible oxidation and reduction during catalytic cycles. By contrast, CX6C disulfides are characteristic of structural bonds that stabilize the domain fold. Their larger loop size creates a geometrically distinct conformation incompatible with the concerted two-electron transfer mechanism of thioredoxin-fold catalysis. Both C449 and C456 reside within the sole canonical thioredoxin domain (approximately residues 392–495), which would be the domain most expected to exhibit catalytic activity if any existed. The fact that even this domain uses a CX6C structural disulfide rather than CXXC further argues against catalytic function.

Riemer et al. confirmed that "Mature ERp90 contains 10 cysteine residues, of which at least some form intramolecular disulfides" (PMID: 21359175), but did not demonstrate that these disulfides undergo catalytic cycling — a critical distinction between structural and active-site disulfides.

Finding 3: TXNDC16 Co-Immunoprecipitates with ERFAD, an ERAD-Pathway Flavoprotein

The strongest functional evidence for TXNDC16 comes from its physical interaction with ERFAD (ER flavoprotein associated with degradation). Riemer et al. (2011) demonstrated co-immunoprecipitation of ERp90/TXNDC16 with ERFAD in cultured human cells and proposed that "the function of ERp90 is related to substrate recruitment or delivery to the ERAD retrotranslocation machinery by ERFAD" (PMID: 21359175).

This interaction is particularly informative when viewed in the context of the broader ERFAD complex. ERFAD itself was characterized by Riemer et al. (2009) as an ER-luminal flavoprotein that interacts with ERAD components SEL1L, OS-9, and ERdj5. The paper demonstrated that "We also identify the ERAD components SEL1L, OS-9 and ERdj5, a known reductase of ERAD substrates, as interaction partners of ERFAD" (PMID: 19706418).

The presence of ERdj5 in this complex is highly significant. ERdj5 (also known as DNAJC10) is a bona fide catalytic reductase with demonstrated disulfide reductase activity — it cleaves disulfide bonds in misfolded proteins to facilitate their retrotranslocation through the Sec61 channel. Ushioda et al. (2008) showed that ERdj5 "had a reductase activity, cleaved the disulfide bonds of misfolded proteins, and accelerated ERAD through its physical and functional associations with EDEM and an ER-resident chaperone BiP" (PMID: 18653895).

The fact that the ERFAD complex already contains a dedicated catalytic reductase (ERdj5) makes it unnecessary — and functionally redundant — for TXNDC16 to possess catalytic activity. Instead, TXNDC16 likely serves as a substrate recognition or hand-off component that captures misfolded glycoproteins and delivers them to ERFAD, which in turn connects them to ERdj5 for disulfide reduction prior to retrotranslocation.

Finding 4: No In Vitro Enzymatic Assay Has Been Published for TXNDC16

Exhaustive PubMed searches for TXNDC16 oxidoreductase activity, ERp90 redox assays, cysteine mutant studies, insulin reduction assays, and disulfide-state mapping experiments returned zero results. The only two primary publications on TXNDC16 are:

Riemer et al. (2011) — characterization, ERFAD interaction, domain architecture (PMID: 21359175)
Harz et al. (2014) — meningioma autoantigen, secretion mechanisms (PMID: 25122923)

Neither reports any in vitro enzymatic assay, cysteine-to-serine mutagenesis, alkylation-based redox-state trapping, or substrate oxidation/reduction experiment. This is a critical absence. For comparison, other PDI-family members with confirmed catalytic function — PDIA1, ERp57, ERp72, ERdj5, TXNDC5 — have all been subjected to extensive biochemical characterization including insulin turbidimetric reduction assays, RNase A refolding/reoxidation assays, redox potential measurements, and cysteine mutant analyses. The complete lack of such data for TXNDC16 after 15 years suggests either that the community does not consider it a likely enzyme, or that attempts to demonstrate activity have failed and gone unreported.

The original authors themselves noted that "other conserved cysteines could endow the protein with redox activity" (PMID: 21359175) — but notably did not test this hypothesis experimentally, despite having the protein in hand.

Finding 5: GO Annotation Supports Only Protein Binding

Query of the Gene Ontology database for TXNDC16 (Q9P2K2) returns only 7 annotations: one molecular function term — protein binding (GO:0005515), with IPI (Inferred from Physical Interaction) evidence from the ERFAD co-immunoprecipitation — and six cellular component terms (ER lumen by IDA, extracellular space/exosome). Critically absent are all enzymatic function annotations:

GO Term	Description	Present for TXNDC16?
GO:0016491	Oxidoreductase activity	No
GO:0003756	Protein disulfide isomerase activity	No
GO:0015036	Disulfide oxidoreductase activity	No
GO:0016853	Isomerase activity	No
GO:0005515	Protein binding	Yes (IPI)

This annotation state reflects the careful curation practice of not extending enzymatic function annotations based solely on domain homology when direct evidence is lacking.

{{figure:txndc16_evidence_synthesis.png|caption=Comprehensive evidence synthesis for TXNDC16/ERp90 molecular function. The weight of evidence across multiple independent lines — sequence analysis, structural features, interaction data, functional assays (or lack thereof), and GO annotation — consistently supports a non-catalytic scaffold role rather than oxidoreductase activity.}}

Mechanistic Model: TXNDC16 as an ERAD Substrate Adaptor

Based on the convergent evidence, we propose the following mechanistic model for TXNDC16 function within the ERAD pathway:

  Misfolded glycoprotein in ER lumen
  |
  v
  ┌───────────────────────┐
  │    TXNDC16/ERp90      │  ◄── Substrate recognition/capture
  │   (scaffold/adaptor)   │      via five thioredoxin-like domains
  │   No CXXC, no redox    │      (hydrophobic binding surfaces,
  │   5× Trx-like folds    │       analogous to PDI b/b' domains)
  └──────────┬────────────┘
     │  substrate hand-off (co-IP confirmed)
     v
  ┌───────────────────────┐
  │        ERFAD           │  ◄── Luminal FAD-containing
  │   (FOXRED2 flavoprotein)│      bridging adaptor
  └──────────┬────────────┘
     │
       ┌─────┴──────┐
       v             v
  ┌──────────┐  ┌───────────┐
  │  SEL1L   │  │   ERdj5   │  ◄── CATALYTIC reductase
  │  OS-9    │  │ (DNAJC10) │      (cleaves substrate disulfides
  │ (lectin  │  │   + BiP   │       via functional CXXC motifs)
  │ sorting) │  └─────┬─────┘
  └────┬─────┘        │
       │              │  reduced, unfolded substrate
       v              v
  ┌───────────────────────┐
  │    HRD1 / Sec61       │  ◄── Retrotranslocation channel
  │  (to cytosol for      │
  │   proteasomal          │
  │   degradation)         │
  └───────────────────────┘

Key Features of This Model

TXNDC16 as a multi-domain binding platform. Its five thioredoxin-like domains — which retain the fold topology but lack catalytic CXXC motifs — provide extensive surface area for substrate binding. This is directly analogous to the well-characterized non-catalytic b and b' domains of canonical PDI (PDIA1), which serve as the primary substrate-binding sites. The crystal structure of PDI's b'-a' domains in complex with a substrate peptide showed that hydrophobic interactions on the b' domain (a non-catalytic Trx-like domain) mediate substrate recognition (PMID: 26350503). TXNDC16 can be understood as a protein in which all five Trx-like domains resemble these non-catalytic substrate-binding domains.
ERFAD as a bridging adaptor. The ERFAD flavoprotein connects TXNDC16-bound substrates to the downstream ERAD machinery. ERFAD's own interaction partners (SEL1L, OS-9, ERdj5) represent the core retrotranslocation-associated complex (PMID: 19706418).
ERdj5 as the dedicated catalytic reductase. ERdj5 possesses the actual CXXC-based reductase activity required to cleave substrate disulfide bonds before retrotranslocation (PMID: 18653895). This division of labor — non-catalytic substrate recognition by TXNDC16 feeding into catalytic processing by ERdj5 — is consistent with the modular organization of ERAD complexes, where substrate selection, processing, and translocation functions are carried out by distinct proteins.
TXNDC16's N-glycosylation (at N460) suggests it may participate in glycan-mediated interactions within the ER lumen, potentially contributing to its ability to recognize misfolded glycoprotein clients.

Distinguishing Direct Catalytic Evidence from Indirect Inference

A critical methodological principle in this analysis is the distinction between direct evidence for catalytic function and indirect inference from family membership, localization, or interaction:

Evidence Type	What It Shows	What It Does NOT Show
Thioredoxin-like domain folds	Structural similarity to catalytic PDIs	Catalytic activity (fold ≠ function)
ER lumen localization	Correct compartment for PDI activity	That the protein is enzymatically active
ERFAD co-immunoprecipitation	Physical interaction with ERAD complex	Catalytic role (could be scaffold/adaptor)
Presence of 10 cysteines	Potential for disulfide chemistry	That any cysteine participates in catalysis
PDI-family classification	Evolutionary relationship by fold homology	Conservation of catalytic function
Intramolecular disulfides	Structural stabilization	Catalytic cycling between redox states

None of the available evidence for TXNDC16 falls in the "direct catalytic evidence" category. Direct evidence would require:
- In vitro oxidoreductase activity (e.g., insulin reduction, RNase refolding)
- Demonstration that cysteine mutations abolish a measurable enzymatic function
- Redox-state cycling of cysteines during substrate processing
- Measurement of reduction potential for any cysteine pair

All of these remain untested for TXNDC16.

Evidence Base: Key Literature

Primary Literature on TXNDC16

Reference	Key Contribution	PMID
Riemer et al. (2011), "Identification of the PDI-family member ERp90 as an interaction partner of ERFAD"	Original characterization; domain architecture; ERFAD co-IP; proposed scaffold function; noted absence of CXXC	21359175
Harz et al. (2014), "Secretion and immunogenicity of the meningioma-associated antigen TXNDC16"	Secretion via masked KDEL; meningioma autoantigen; cytosolic localization	25122923

ERFAD and ERAD Pathway Literature

Reference	Relevance	PMID
Riemer et al. (2009), "A luminal flavoprotein in ER-associated degradation"	Characterized ERFAD and its interactions with SEL1L, OS-9, ERdj5	19706418
Ushioda et al. (2008), "ERdj5 is required as a disulfide reductase for degradation of misfolded proteins in the ER"	Demonstrated ERdj5's catalytic reductase activity in ERAD; showed it cleaves substrate disulfides	18653895

CXXC Motif and PDI Catalysis Literature

Reference	Relevance	PMID
Chivers et al. (1996), "The CXXC motif: imperatives for the formation of native disulfide bonds in the cell"	Established CXXC as necessary and sufficient for cellular disulfide bond formation	8654363
Jäger et al. (1997), "Active site mutations in yeast PDI cause DTT sensitivity and reduced protein folding"	Showed CXXC→SGAS mutation abolishes PDI catalytic activity in vivo	9298979
Ren et al. (1999), "The CXXC motif: crystal structure of an active-site variant of E. coli thioredoxin"	Structural basis for CXXC reduction potential; the motif tunes cysteine pKa	10489448
Yagi-Utsumi et al. (2015), "Structural basis of redox-dependent substrate binding of PDI"	Showed how PDI's non-catalytic b' domain mediates substrate binding via hydrophobic interactions	26350503

Contextual PDI-Family Reviews

The broader PDI-family literature consistently reinforces that catalytic activity requires CXXC motifs. Reviews of the 21-member human PDI family (PMID: 35965326, PMID: 39319369) emphasize the thioredoxin domain CXXC motif as the signature of catalytic members. The recent ROB-Fold structural analysis explicitly used the CXXC motif as the anchor for identifying the conserved catalytic scaffold across PDI-family members (PMID: 42253318). TXNDC16's absence from catalytic discussions in these comprehensive reviews is itself informative and consistent with its non-catalytic status.

The characterization of other thioredoxin-domain-containing proteins with confirmed catalytic activity — such as TXNDC5 (PMID: 38629066, PMID: 35934705), which has three Trx-like domains each with functional CXXC motifs — provides a useful contrast. TXNDC5 has been extensively characterized with purified-protein assays demonstrating disulfide isomerase activity, underscoring the feasibility of such experiments and making TXNDC16's 15-year lack of enzymatic data all the more conspicuous.

Limitations and Knowledge Gaps

What We Do Not Know

No crystal or cryo-EM structure of TXNDC16 exists. AlphaFold predictions provide fold models but cannot reveal whether noncanonical cysteines are positioned in geometries that might allow unconventional redox chemistry.
No in vitro biochemistry has been performed. While the absence of CXXC makes catalytic activity unlikely, it cannot be formally excluded without direct testing. Some non-canonical oxidoreductases exist (e.g., certain single-cysteine mechanisms in bacterial DsbA-like proteins), though these are rare and mechanistically distinct from PDI-family catalysis.
The precise substrate repertoire of TXNDC16 is unknown. Which misfolded proteins it recognizes, and whether recognition requires its thioredoxin-like domains or glycan-binding properties, has not been determined.
The stoichiometry and dynamics of the TXNDC16–ERFAD interaction are uncharacterized. Whether binding is constitutive or substrate-induced is unknown.
Publication bias: It is possible that negative results from redox assays have been obtained but not published, which would further support the non-catalytic conclusion but remains invisible in the literature.
Small literature base: Only two primary publications exist on TXNDC16 itself, limiting the diversity of experimental approaches that have been applied. The protein remains understudied relative to other PDI-family members.

Caveats

Absence of evidence is not evidence of absence — the non-catalytic conclusion, while strongly supported, remains a default inference pending direct experimental testing.
The CX6C disulfide at C449–C456 could theoretically participate in non-canonical redox chemistry under specific conditions, though no evidence supports this and the spacing is inconsistent with known catalytic mechanisms.
TXNDC16's secretion (shown by PMID: 25122923) raises the possibility of extracellular functions that have not been explored — though any such function would be distinct from intracellular PDI-type catalysis.

Proposed Follow-up Experiments

Priority 1: Definitive Enzymatic Testing

Purified recombinant TXNDC16 in standard PDI assays: Express and purify full-length TXNDC16 and test in:
Insulin turbidimetric reduction assay (reductase activity)
Scrambled RNase A refolding assay (isomerase activity)
Di-E-GSSG fluorescent assay (oxidase activity)
Compare to PDIA1 positive control and buffer-only negative control
Cysteine-to-serine mutagenesis panel: Systematically mutate each of the 10 mature cysteines (individually and in combinations, especially C449S, C456S, C84S, C93S) and test for:
Loss of any detectable redox activity (if found in experiment 1)
Loss of ERFAD binding
Loss of ERAD substrate recruitment function

Priority 2: Redox-State Characterization

Differential alkylation / redox-state trapping: Treat cells with NEM (to trap free thiols) vs. DTT+NEM (to reduce then trap all cysteines), followed by mass spectrometry, to determine which cysteines are in disulfide bonds vs. free thiols under native ER conditions.
Redox-dependent mobility shift: Use AMS/mPEG-mal alkylation followed by non-reducing SDS-PAGE to determine whether TXNDC16 cysteines undergo redox cycling in response to ER stress or substrate load.

Priority 3: Substrate and Complex Characterization

Proximity labeling (BioID/TurboID) of TXNDC16 to identify its full interactome and potential substrates in the ER lumen.
TXNDC16 knockout / knockdown followed by measurement of ERAD kinetics for model substrates (e.g., NHK/null Hong Kong variant of alpha-1 antitrypsin, ribophorin 332) to determine whether loss of TXNDC16 delays substrate degradation.
Co-immunoprecipitation under varying redox conditions to determine whether TXNDC16–ERFAD interaction is redox-sensitive (which would suggest functional coupling to the redox state of the complex).

Priority 4: Structural Biology

AlphaFold Multimer prediction of the TXNDC16–ERFAD complex to identify the binding interface and predict whether any TXNDC16 cysteines are positioned near the interaction surface.
Cryo-EM of the TXNDC16–ERFAD complex to determine the structural basis of their interaction and the spatial relationship between TXNDC16's thioredoxin-like domains and ERFAD's FAD cofactor.

Defensible Molecular Function Annotation

Annotation	Defensible?	Basis
Protein binding (GO:0005515)	Yes	IPI evidence from ERFAD co-IP (PMID: 21359175)
Oxidoreductase activity (GO:0016491)	No	No CXXC, no enzymatic assay, no direct evidence
Protein disulfide isomerase activity (GO:0003756)	No	No CXXC, no isomerase assay
Disulfide oxidoreductase activity (GO:0015036)	No	No catalytic motif, no redox assay
Unfolded protein binding (GO:0051082)	Plausible but unproven	Consistent with proposed model but not directly demonstrated
ERAD pathway involvement (GO:0030433)	Plausible	ERFAD interaction supports this, but direct evidence of ERAD function for TXNDC16 itself is lacking

Recommended curation: TXNDC16/ERp90 should be annotated as an ER-luminal multi-domain scaffold protein with protein binding function in the context of ERAD. The PDI "family" classification based on Trx-fold homology should be noted as structural, not functional. If a more specific term is needed, "ERAD substrate adaptor/recruiter" would be defensible based on the original authors' own interpretation and the interaction network evidence. Annotating TXNDC16 as an oxidoreductase or disulfide isomerase based solely on the presence of thioredoxin-like folds would be an unjustified inference — the catalytic motifs are absent, and catalytic activity has never been demonstrated. The protein's gene name ("thioredoxin domain-containing 16") accurately describes its structure but should not be mistaken as evidence for enzymatic function.

References

Riemer J, Hansen HG, Appenzeller-Herzog C, Johansson L, Ellgaard L. Identification of the PDI-family member ERp90 as an interaction partner of ERFAD. J Cell Sci. 2011;124(Pt 7):1117-1126. PMID: 21359175
Riemer J, Appenzeller-Herzog C, Johansson L, Bodenmiller B, Hartmann-Petersen R, Ellgaard L. A luminal flavoprotein in endoplasmic reticulum-associated degradation. Proc Natl Acad Sci USA. 2009;106(35):14831-14836. PMID: 19706418
Harz C, Ludwig N, Lang S, et al. Secretion and immunogenicity of the meningioma-associated antigen TXNDC16. J Immunol. 2014;193(7):3146-3154. PMID: 25122923
Ushioda R, Hoseki J, Araki K, Jansen G, Thomas DY, Nagata K. ERdj5 is required as a disulfide reductase for degradation of misfolded proteins in the ER. Science. 2008;321(5888):569-572. PMID: 18653895
Yagi-Utsumi M, Satoh T, Kato K. Structural basis of redox-dependent substrate binding of protein disulfide isomerase. Sci Rep. 2015;5:13909. PMID: 26350503
Chivers PT, Laboissiere MC, Raines RT. The CXXC motif: imperatives for the formation of native disulfide bonds in the cell. EMBO J. 1996;15(11):2659-2667. PMID: 8654363
Jäger M, Dendle M, Kelly JW. Active site mutations in yeast protein disulfide isomerase cause dithiothreitol sensitivity and a reduced rate of protein folding in the endoplasmic reticulum. J Biol Chem. 1997;272(18):11749-11756. PMID: 9298979
Ren G, et al. The CXXC motif: crystal structure of an active-site variant of Escherichia coli thioredoxin. Protein Sci. 1999;8(10):2089-2095. PMID: 10489448
Sato Y, et al. Functions and mechanisms of protein disulfide isomerase family in cancer emergence. Cell Death Discov. 2022;8:407. PMID: 35965326
Zhang X, et al. The role of protein disulfide isomerase inhibitors in cancer therapy. Molecules. 2024;29(18):4389. PMID: 39319369
Bonadio RS, et al. Nature's economy as blueprint: regional overlap & block-based algorithm for protein design. BMC Bioinformatics. 2025;26:127. PMID: 42253318

OpenScientist prompt: TXNDC16/ERp90 redox activity versus non-catalytic scaffold function

(TXNDC16-hypotheses/kgap-txndc16-redox-vs-scaffold/prompt.md)

OpenScientist prompt: TXNDC16/ERp90 redox activity versus non-catalytic scaffold function

Investigate whether human TXNDC16/ERp90 is a catalytic PDI-family oxidoreductase using noncanonical cysteines, or instead acts as a non-catalytic ER-luminal scaffold/adaptor, including ERFAD-dependent substrate handoff.

Focus on:

domain architecture and conservation of thioredoxin-like domains and noncanonical cysteines;
evidence for or against redox chemistry, disulfide isomerase activity, or substrate oxidation/reduction;
cysteine-mutant, disulfide-state mapping, and purified-protein assays;
ERFAD interaction and whether it indicates substrate handling rather than catalysis.

Please distinguish direct catalytic evidence from localization, interaction, and family inference. Include PMIDs and conclude which molecular-function curation would be defensible now.

📚 Additional Documentation

Notes

(TXNDC16-notes.md)

TXNDC16 (Q9P2K2) review notes

Identity

Thioredoxin domain-containing protein 16; alias ERp90, KIAA1344. HGNC:19965. 825 aa precursor (signal peptide 1-27; chain 28-825).
Large soluble ER-luminal glycoprotein of the PDI family with multiple (five) potential thioredoxin (Trx)-like domains. UniProt annotates one Trx domain 392-495, N-glycosylation at N460, intramolecular disulfide 449-456.
C-terminal sequence has a MASKED, NON-FUNCTIONAL KDEL-like ER-retrieval motif (816-819), which permits partial secretion.
UniProt has NO FUNCTION block and NO redox-active CXXC feature: the catalytic status is uncertain/likely redox-inactive.

Key functional evidence

PMID:21359175 (Riemer et al. 2011, "Identification of the PDI-family member ERp90 as an interaction partner of ERFAD") — full text cached

"we identify the previously uncharacterized PDI-family member ERp90. In cultured human cells, we find ERp90 to be a soluble ER-luminal glycoprotein that comprises five potential thioredoxin (Trx)-like domains."
"Mature ERp90 contains 10 cysteine residues, of which at least some form intramolecular disulfides. While none of the Trx domains contain a canonical Cys-Xaa-Xaa-Cys active-site motif, other conserved cysteines could endow the protein with redox activity."
"ERp90 co-immunoprecipitates with ERFAD, a flavoprotein involved in ER-associated degradation (ERAD), through what is most likely a direct interaction. We propose that the function of ERp90 is related to substrate recruitment or delivery to the ERAD retrotranslocation machinery by ERFAD."
ERFAD = FOXRED2 (UniProt Q8IWF2). The IPI protein binding annotation (PMID:21359175, with FOXRED2) is the functionally meaningful interaction (ERAD context), unlike typical HT captures, but is still a bare protein binding term.

PMID:25122923 (Harz et al. 2014, "Secretion and immunogenicity of the meningioma-associated antigen TXNDC16") — abstract only cached

"TXNDC16 was previously found to be an endoplasmic reticulum (ER)-luminal glycoprotein."
"we show an additional ER-associated localization of TXNDC16 in the cytosol ... We were able to show TXNDC16 secretion in different human cell lines due to masked and therefore nonfunctional ER retrieval motif."
"A previously indicated exosomal TXNDC16 secretion could not be confirmed in HEK293 cells." -> casts doubt on the exosome (PMID:19199708 HDA) localization.
Meningioma-associated antigen; autoantibodies in patient sera; secreted serum protein in circulating immune complexes. Basis of the GO:0005576 extracellular region (EXP/IEA Secreted) annotations.

PMID:19199708 (parotid gland exosome MudPIT proteomics) — HDA extracellular exosome

High-throughput proteomic detection in exosomes. Note PMID:25122923 could NOT confirm exosomal secretion in HEK293; treat as non-core / uncertain.

Redox/catalytic status

No canonical CXXC in any Trx domain -> likely a redox-inactive / pseudo-thioredoxin scaffold (like the b-type PDI domains), possibly contributing to substrate recruitment/delivery rather than direct thiol-disulfide catalysis. Do NOT assert protein disulfide isomerase activity as a confirmed core MF; the evidence does not support a catalytic CXXC.

GOA assessment

GO:0005788 ER lumen (IEA SubCell + EXP PMID:25122923 + IDA PMID:21359175) — ACCEPT (primary localization).
GO:0005576 extracellular region (IEA Secreted + EXP PMID:25122923) — KEEP_AS_NON_CORE (secreted due to masked KDEL; real but secondary).
GO:0005515 protein binding (IPI, PMID:21359175, FOXRED2/ERFAD) — KEEP_AS_NON_CORE (functionally meaningful ERAD interaction but bare protein binding term; suggest a more informative MF if ERAD adapter role confirmed).
GO:0070062 extracellular exosome (HDA, PMID:19199708) — KEEP_AS_NON_CORE / uncertain; exosomal secretion was not confirmed in a later study (PMID:25122923).

Core function summary

TXNDC16/ERp90 is an ER-luminal PDI-family glycoprotein lacking a canonical CXXC redox motif; its best-supported role is as an interaction partner of the ERAD flavoprotein ERFAD/FOXRED2, proposed to function in substrate recruitment/delivery to the ERAD retrotranslocation machinery. It is partly secreted (masked KDEL) and is a meningioma-associated antigen. Core MF is not a confirmed catalytic oxidoreductase activity; propose no strong catalytic MF. BP = likely ERAD-related (proposed). CC = ER lumen (primary).

Falcon deep-research findings (incorporated 2026-06)

Review-level corroboration of non-catalytic status: Patel et al. 2020 (Cells; PubMed-verified PMID:32971745) explicitly classify ERp90/TXNDC16 as non-catalytic, with non-canonical Trx-like motifs (reported as Trxl1-CX8C, Trxl2-CX9C, Trxl3-CX6C, Trxl4/5 inactive) rather than active CXXC PMID:32971745. This is review/family-level inference consistent with the primary finding (PMID:21359175) that none of the Trx domains carry a canonical CXXC; do NOT over-claim a defined catalytic reaction.
The same review places ERp90/TXNDC16 in the ERAD (retrotranslocation) category and reports associations with the ERAD lectin OS-9 and adaptor SEL1L PMID:32971745. These are secondary-source associations (not gene-specific primary co-IP data in the retrieved corpus), so they are recorded as context only and not added as annotations.
Biomarker context (review): Korte & Mathios 2024 (Int J Mol Sci; PubMed-verified PMID:38673779) review TXNDC16 as a meningioma-associated antigen and restate that a five-epitope autoantibody panel (from 163 overlapping peptides) discriminated meningioma vs controls with ~90% sensitivity and ~83.7% specificity, framing it as a proof-of-concept liquid-biopsy serology marker PMID:38673779. This restates the existing Harz 2014 (PMID:25122923) primary findings; contextual/disease relevance only.
Falcon confirms (via Harz 2014, already cited as PMID:25122923) the signal-peptide dependence of ER targeting: deleting the N-terminal 27-aa signal peptide shifted TXNDC16 from ER-associated to cytosolic localization, and that ER retention is incomplete due to a masked DKEL retrieval motif [PMID:25122923 (Harz 2014); restated in PMID:38673779]. Already captured in the review.
No new gene-specific mechanistic 2023-2025 primary studies of human TXNDC16 were surfaced; a 2024 PNAS mouse-testis WFDC-cluster knockout proteomics study (Kent et al., PMID/DOI:10.1073/pnas.2413195121) merely notes TXNDC16 upregulation among protein-degradation/quality-control proteins - directionally consistent with an ERAD/quality-control role but NOT human gene-specific mechanistic proof; notes-only, not added to YAML.
A 2025 ER-redoxome review (Oliveira et al., DOI:10.1021/acs.biochem.5c00527) lists TXNDC16/ERp90 among ER PDI/thioredoxin-domain proteins without adding TXNDC16-specific mechanistic detail; background only.
Net: the core ERFAD/FOXRED2-linked ERAD substrate-recruitment role and the non-catalytic (no canonical CXXC) classification already in the review remain the best-supported picture; Falcon adds review-level corroboration plus the meningioma biomarker context, no change to actions.

Pn Notes

(TXNDC16-pn-notes.md)

TXNDC16 PN Consistency Notes

Generated: 2026-06-18
Project: PROTEOSTASIS
Scope: PN consistency rereview against local AIGR review and available deep-research artifacts
UniProt: Q9P2K2
AIGR review status: COMPLETE
Review batch: proteostasis-batch-2026-06-11
Batch change status: added

Source Files Checked

AIGR review YAML: present - genes/human/TXNDC16/TXNDC16-ai-review.yaml
AIGR review HTML: missing - genes/human/TXNDC16/TXNDC16-ai-review.html
Gene notes: present - genes/human/TXNDC16/TXNDC16-notes.md
GOA TSV: present - genes/human/TXNDC16/TXNDC16-goa.tsv
UniProt record: present - genes/human/TXNDC16/TXNDC16-uniprot.txt
PN dossier: projects/PROTEOSTASIS/reports/phase1_dossiers/TXNDC16.md
PN consistency section: projects/PROTEOSTASIS/reports/phase1_dossiers/_sections/TXNDC16.md
PN projection report: projects/PROTEOSTASIS/reports/pn_projection/pn_projected_gene_go_summary.tsv
PN mapping audit: projects/PROTEOSTASIS/reports/pn_mapping_audit/current_mapping_scrutiny.tsv

Deep Research Files

genes/human/TXNDC16/TXNDC16-deep-research-falcon.md

AIGR Review Snapshot

Description: TXNDC16 (Thioredoxin domain-containing protein 16; also called ERp90 or KIAA1344) is a large (825 aa precursor) soluble glycoprotein of the protein disulfide isomerase (PDI) family resident in the endoplasmic reticulum lumen. After signal-peptide cleavage it comprises several (about five) thioredoxin (Trx)-like domains and is N-glycosylated, with at least some of its cysteines forming intramolecular disulfides. Notably, none of its Trx domains contains a canonical Cys-Xaa-Xaa-Cys redox active-site motif, so it is likely a redox-inactive or non-catalytic PDI-family member whose precise enzymatic activity remains uncharacterized. Its best-supported molecular role is as a direct interaction partner of the ER-associated degradation (ERAD) flavoprotein ERFAD (FOXRED2), suggesting a function in recruitment or delivery of substrates to the ERAD retrotranslocation machinery. TXNDC16 carries a masked, non-functional KDEL-type ER-retrieval motif and is therefore partly secreted into the extracellular space; it has been described as a meningioma-associated antigen against which patient autoantibodies arise.
Existing/core annotation action counts: ACCEPT: 3; KEEP_AS_NON_CORE: 4

PN Consistency Summary

Consistency: CONTRADICTION. The review and notes (and deep research) explicitly conclude TXNDC16/ERp90 is a non-catalytic PDI-family member: none of its ~five Trx-like domains carry a canonical CXXC redox motif (PMID:21359175; review PMID:32971745 corroborates non-canonical CX8C/CX9C/CX6C motifs). The review asserts no catalytic oxidoreductase MF, leaves proposed_new_terms: [], and frames the best-supported role as an ERFAD/FOXRED2 ERAD-substrate-recruitment partner. The PN projects GO:0003756 protein disulfide isomerase activity (verified real via OLS) onto this gene by virtue of family membership — directly at odds with the gene-level finding of redox inactivity.
PN story / NEW pressure: PN asserts PDI activity NOT in GOA (GOA has only GO:0005515 + localizations). But this is an OVER-REACH: catalytic PDI activity is contradicted by the absence of a CXXC active site. No defensible catalytic NEW term; an ERAD substrate-recruitment/adapter MF is plausible but unproven (review keeps it a suggested question). Conclude: PN PDI-activity projection over-reaches for THIS gene.
Evidence alignment: PN row carries no reference titles. Review evidence (PMID:21359175 HIGH/VERIFIED defining paper; PMID:25122923, 32971745, 19199708, 38673779) is far richer and all point to non-catalytic status. No shared citations to compare; no divergence beyond the PN's family-level inference lacking gene-specific support.
Verdict: Inconsistent on the one substantive point — PN projects PDI catalytic activity that the review/literature refute (no CXXC). Review is correct; PN projection over-reaches.

Full Consistency Review

UniProt: Q9P2K2 · batch: proteostasis-batch-2026-06-11 · review status: COMPLETE (thorough; ER-luminal PDI-family glycoprotein, ERFAD/FOXRED2 partner)
PN placement: 1 row — ER proteostasis|Folding enzyme|Protein disulfide isomerases. PN-node mapping: group→mapped GO:0003756 protein disulfide isomerase activity (ok_for_propagation_to_go, new_to_goa); class (Folding enzyme) and branch (ER proteostasis) no_mapping. Projected: GO:0003756 (new_to_goa).
Consistency: CONTRADICTION. The review and notes (and deep research) explicitly conclude TXNDC16/ERp90 is a non-catalytic PDI-family member: none of its ~five Trx-like domains carry a canonical CXXC redox motif (PMID:21359175; review PMID:32971745 corroborates non-canonical CX8C/CX9C/CX6C motifs). The review asserts no catalytic oxidoreductase MF, leaves proposed_new_terms: [], and frames the best-supported role as an ERFAD/FOXRED2 ERAD-substrate-recruitment partner. The PN projects GO:0003756 protein disulfide isomerase activity (verified real via OLS) onto this gene by virtue of family membership — directly at odds with the gene-level finding of redox inactivity.
PN story / NEW pressure: PN asserts PDI activity NOT in GOA (GOA has only GO:0005515 + localizations). But this is an OVER-REACH: catalytic PDI activity is contradicted by the absence of a CXXC active site. No defensible catalytic NEW term; an ERAD substrate-recruitment/adapter MF is plausible but unproven (review keeps it a suggested question). Conclude: PN PDI-activity projection over-reaches for THIS gene.
Mapping strategy: The group→GO:0003756 mapping is reasonable for the canonical catalytic PDIs but should NOT propagate to TXNDC16, a redox-inactive family member (analogous to ERp27/ERp29 b-type pseudo-PDIs). This is a member-level exclusion, not a node-status change: the group mapping rationale already says "catalytically active family members," so TXNDC16 falls outside that scope.
Evidence alignment: PN row carries no reference titles. Review evidence (PMID:21359175 HIGH/VERIFIED defining paper; PMID:25122923, 32971745, 19199708, 38673779) is far richer and all point to non-catalytic status. No shared citations to compare; no divergence beyond the PN's family-level inference lacking gene-specific support.
Verdict: Inconsistent on the one substantive point — PN projects PDI catalytic activity that the review/literature refute (no CXXC). Review is correct; PN projection over-reaches.
Recommended edits: [MAP] Exclude TXNDC16 (Q9P2K2) from the GO:0003756 protein disulfide isomerase activity projection (redox-inactive PDI-family member, no CXXC) — flag as member-level exception under the "Protein disulfide isomerases" group, do NOT project to GOA. [YAML] none required (review correctly omits a catalytic MF).

PN Dossier Context

review_batch: proteostasis-batch-2026-06-11
review_yaml: genes/human/TXNDC16/TXNDC16-ai-review.yaml
PN workbook rows: 1

PN row 1: ER proteostasis | Folding enzyme | Protein disulfide isomerases

UniProt: Q9P2K2
In branches: ER
PN-node mapping records (path + ancestors):
- [group] ER proteostasis|Folding enzyme|Protein disulfide isomerases
  status=mapped scope=ok_for_propagation_to_go GO=[GO:0003756 protein disulfide isomerase activity]
  rationale: This PN group captures the canonical ER protein-disulfide-isomerase folding enzymes. GO protein disulfide isomerase activity is the cleanest propagation target for the catalytically active family members.
- [class] ER proteostasis|Folding enzyme
  status=no_mapping scope= GO=[]
  rationale: Reviewed as a broad PN category rather than a single GO class. The member genes span multiple activities, complexes, or contexts, so direct propagation from this node would overstate the shared biology.
- [branch] ER proteostasis
  status=no_mapping scope= GO=[]
  rationale: Reviewed as a top-level PN branch. This is a systems/taxonomy umbrella, not a direct GO assertion; narrower child curations carry any propagating GO mappings.

Projected GO annotations (1)

GO:0003756 protein disulfide isomerase activity | scope=ok_for_propagation_to_go | goa_status=new_to_goa | from=ER proteostasis|Folding enzyme|Protein disulfide isomerases

Note

This file is generated from the current PROTEOSTASIS phase-1 dossier and local gene-review artifacts. Edit the source review, PN mapping, or dossier rather than this generated note when correcting the underlying curation.

📄 View Raw YAML

id: Q9P2K2
gene_symbol: TXNDC16
product_type: PROTEIN
status: COMPLETE
taxon:
  id: NCBITaxon:9606
  label: Homo sapiens
description: >-
  TXNDC16 (Thioredoxin domain-containing protein 16; also called ERp90 or KIAA1344) is a
  large (825 aa precursor) soluble glycoprotein of the protein disulfide isomerase (PDI)
  family resident in the endoplasmic reticulum lumen. After signal-peptide cleavage it
  comprises several (about five) thioredoxin (Trx)-like domains and is N-glycosylated, with
  at least some of its cysteines forming intramolecular disulfides. Notably, none of its Trx
  domains contains a canonical Cys-Xaa-Xaa-Cys redox active-site motif, so it is likely a
  redox-inactive or non-catalytic PDI-family member whose precise enzymatic activity remains
  uncharacterized. Its best-supported molecular role is as a direct interaction partner of the
  ER-associated degradation (ERAD) flavoprotein ERFAD (FOXRED2), suggesting a function in
  recruitment or delivery of substrates to the ERAD retrotranslocation machinery. TXNDC16
  carries a masked, non-functional KDEL-type ER-retrieval motif and is therefore partly
  secreted into the extracellular space; it has been described as a meningioma-associated
  antigen against which patient autoantibodies arise.
existing_annotations:
- term:
    id: GO:0005576
    label: extracellular region
  evidence_type: IEA
  original_reference_id: GO_REF:0000044
  qualifier: located_in
  review:
    summary: >-
      Electronic (UniProt SubCell "Secreted") assignment of extracellular localization. TXNDC16
      is partly secreted because its KDEL-type ER-retrieval motif is masked and non-functional.
      This is a real but secondary localization relative to its primary ER-lumen residence.
    action: KEEP_AS_NON_CORE
    reason: >-
      Secretion is genuine but secondary; the protein's primary site is the ER lumen.
    supported_by:
    - reference_id: file:human/TXNDC16/TXNDC16-uniprot.txt
      supporting_text: 'SUBCELLULAR LOCATION: Secreted'
- term:
    id: GO:0005788
    label: endoplasmic reticulum lumen
  evidence_type: IEA
  original_reference_id: GO_REF:0000044
  qualifier: located_in
  review:
    summary: >-
      Electronic assignment of ER-lumen localization, consistent with the experimental IDA/EXP
      annotations and the curated subcellular location. This is the primary site of TXNDC16.
    action: ACCEPT
    reason: >-
      Correct primary localization; TXNDC16/ERp90 is a soluble ER-luminal glycoprotein.
    supported_by:
    - reference_id: file:human/TXNDC16/TXNDC16-uniprot.txt
      supporting_text: Endoplasmic reticulum lumen
- term:
    id: GO:0005576
    label: extracellular region
  evidence_type: EXP
  original_reference_id: PMID:25122923
  qualifier: located_in
  review:
    summary: >-
      Experimental demonstration that TXNDC16 is secreted from human cell lines because its ER
      retrieval motif is masked and non-functional. A real but secondary localization.
    action: KEEP_AS_NON_CORE
    reason: >-
      Genuine secretion arising from the masked KDEL motif, but secondary to the primary ER-lumen
      localization.
    supported_by:
    - reference_id: PMID:25122923
      supporting_text: >-
        We were able to show TXNDC16 secretion in different human cell lines due to masked and
        therefore nonfunctional ER retrieval motif.
- term:
    id: GO:0005788
    label: endoplasmic reticulum lumen
  evidence_type: EXP
  original_reference_id: PMID:25122923
  qualifier: located_in
  review:
    summary: >-
      Experimental confirmation of the ER-luminal glycoprotein localization of TXNDC16.
    action: ACCEPT
    reason: >-
      Correct primary localization, consistent with the IDA and electronic annotations.
    supported_by:
    - reference_id: PMID:25122923
      supporting_text: >-
        TXNDC16 was previously found to be an endoplasmic reticulum (ER)-luminal glycoprotein.
- term:
    id: GO:0005515
    label: protein binding
  evidence_type: IPI
  original_reference_id: PMID:21359175
  qualifier: enables
  review:
    summary: >-
      Co-immunoprecipitation showing TXNDC16/ERp90 directly interacts with ERFAD (FOXRED2), an
      ER flavoprotein involved in ERAD. This is the functionally most informative interaction for
      TXNDC16, suggesting an ERAD substrate-recruitment/delivery role, but the bare protein
      binding term itself is uninformative.
    action: KEEP_AS_NON_CORE
    reason: >-
      Records a genuine, functionally meaningful ERAD-related interaction, but per guidelines bare
      protein binding is not elevated to a core molecular function; a more specific adapter/ERAD
      term would be preferable if the role is confirmed.
    supported_by:
    - reference_id: PMID:21359175
      supporting_text: >-
        ERp90 co-immunoprecipitates with ERFAD, a flavoprotein involved in ER-associated
        degradation (ERAD), through what is most likely a direct interaction.
- term:
    id: GO:0005788
    label: endoplasmic reticulum lumen
  evidence_type: IDA
  original_reference_id: PMID:21359175
  qualifier: located_in
  review:
    summary: >-
      Direct evidence that ERp90/TXNDC16 is a soluble ER-luminal glycoprotein.
    action: ACCEPT
    reason: >-
      Experimentally supported primary localization.
    supported_by:
    - reference_id: PMID:21359175
      supporting_text: >-
        we find ERp90 to be a soluble ER-luminal glycoprotein that comprises five potential
        thioredoxin (Trx)-like domains.
- term:
    id: GO:0070062
    label: extracellular exosome
  evidence_type: HDA
  original_reference_id: PMID:19199708
  qualifier: located_in
  review:
    summary: >-
      High-throughput proteomic detection of TXNDC16 in parotid-gland exosomes. A later study
      could not confirm exosomal secretion in HEK293 cells, so this localization is uncertain;
      retained as non-core rather than removed since it is a proteomics-based experimental
      detection.
    action: KEEP_AS_NON_CORE
    reason: >-
      Proteomic detection in exosomes that was not reproduced in a subsequent study (PMID:25122923);
      uncertain and non-core, but not removed on weak grounds.
    supported_by:
    - reference_id: PMID:25122923
      supporting_text: >-
        A previously indicated exosomal TXNDC16 secretion could not be confirmed in HEK293 cells.
core_functions:
- description: >-
    ER-luminal PDI-family glycoprotein that lacks a canonical CXXC redox motif and acts as a
    direct interaction partner of the ERAD flavoprotein ERFAD (FOXRED2), proposed to function in
    recruitment or delivery of substrates to the ERAD retrotranslocation machinery.
  locations:
  - id: GO:0005788
    label: endoplasmic reticulum lumen
  supported_by:
  - reference_id: PMID:21359175
    supporting_text: >-
      We propose that the function of ERp90 is related to substrate recruitment or delivery to
      the ERAD retrotranslocation machinery by ERFAD.
knowledge_gaps:
- gap_statement: >-
    It is unresolved whether TXNDC16/ERp90 is a purely non-catalytic PDI-family
    scaffold/adaptor or whether it performs a CXXC-independent redox activity using
    conserved noncanonical cysteines.
  boundary: >-
    ERp90 is a soluble ER-luminal PDI-family glycoprotein with five Trx-like domains
    and no canonical Cys-Xaa-Xaa-Cys active-site motif; some cysteines form
    intramolecular disulfides. The open question is whether those noncanonical
    cysteines are structural only or contribute directly to redox chemistry.
  gap_kind:
  - BIOLOGY
  - ONTOLOGY
  dark_aspect: MF_DARK
  status: OPEN
  significance: >-
    The molecular function cannot be curated more specifically than ER-lumen
    localization and ERFAD binding until this distinction is resolved; a catalytic
    oxidoreductase role and a non-catalytic substrate-adaptor role imply different
    GO molecular functions.
  resolution: >-
    Purify full-length ERp90 and cysteine mutants for redox assays, disulfide-state
    mapping, and ERFAD-dependent substrate handoff assays in parallel with cellular
    rescue experiments.
  provenance:
  - reference_id: PMID:21359175
    supporting_text: >-
      While none of the Trx domains contain a canonical Cys-Xaa-Xaa-Cys active-site
      motif, other conserved cysteines could endow the protein with redox activity.
    reference_section_type: ABSTRACT
  - reference_id: PMID:21359175
    supporting_text: >-
      Finally, ERp90 could perform a CXXC-independent redox function, conceivably
      in collaboration with the redox-active ERFAD, through the conserved C664 or
      even the CX9C motif in the Trx2.
    reference_section_type: DISCUSSION
- gap_statement: >-
    The ERAD substrate set and pathway step that depend on TXNDC16 remain unknown.
    ERp90 is proposed to help ERFAD recruit or deliver substrates to the
    retrotranslocation machinery, but no endogenous substrates or loss-of-function
    ERAD defects have been demonstrated.
  boundary: >-
    TXNDC16/ERp90 physically associates with ERFAD/FOXRED2 and is positioned in the
    ERAD luminal network. What is missing is functional evidence that specific
    glycoprotein or disulfide-containing ERAD clients require TXNDC16 for
    recognition, reduction, handoff to SEL1L/OS-9, retrotranslocation, or degradation.
  gap_kind:
  - BIOLOGY
  dark_aspect: BP_DARK
  status: OPEN
  significance: >-
    This gap separates an interaction-based ERAD hypothesis from a process
    annotation. Resolving it would define whether TXNDC16 is a core ERAD factor,
    a client-specific cofactor, or a bystander in an ERFAD-containing complex.
  resolution: >-
    Generate TXNDC16 knockout/rescue cells and measure degradation, disulfide status,
    and retrotranslocation of model and proteome-wide ERAD substrates, including
    ERFAD-dependent and ERFAD-independent contexts.
  provenance:
  - reference_id: PMID:21359175
    supporting_text: >-
      Since we did not succeed in performing siRNA-mediated knockdown experiments
      of ERp90 to study an involvement of ERp90 in ERAD, we can presently only
      speculate about the function of ERp90 in relation to ERFAD.
    reference_section_type: DISCUSSION
  - reference_id: PMID:21359175
    supporting_text: >-
      Future work should allow us to distinguish between these various
      possibilities.
    reference_section_type: DISCUSSION
- gap_statement: >-
    The biological significance of TXNDC16 secretion and meningioma-associated
    autoantibodies is unclear. TXNDC16 is secreted because its ER-retrieval motif is
    masked, and antibodies can distinguish meningioma sera, but it is not known
    whether extracellular TXNDC16 has a function or is mainly a biomarker/immunogenic
    byproduct of leakage from the ER-lumen pool.
  boundary: >-
    Secretion from multiple human cell lines and circulating immune complexes are
    documented, while exosomal secretion was not confirmed in HEK293 cells. The
    unresolved part is whether secreted TXNDC16 participates in disease biology,
    antigen presentation, or immune-complex formation beyond diagnostic association.
  gap_kind:
  - BIOLOGY
  - CURATION
  dark_aspect: RESIDUAL_SUBGAP
  status: OPEN
  significance: >-
    This limits curation of extracellular annotations: secretion is real and should
    be retained, but disease-associated immunogenicity should not be interpreted as
    a normal extracellular molecular function without mechanistic evidence.
  resolution: >-
    Determine the source and form of serum TXNDC16 in meningioma and controls,
    test whether immune complexes contain intact secreted protein or fragments, and
    assess any extracellular effects on immune or tumor cells.
  provenance:
  - reference_id: PMID:25122923
    supporting_text: >-
      We were able to show TXNDC16 secretion in different human cell lines due to
      masked and therefore nonfunctional ER retrieval motif.
    reference_section_type: ABSTRACT
  - reference_id: PMID:25122923
    supporting_text: >-
      The secreted serum protein TXNDC16 is bound in circulating immune complexes,
      which were found both in meningioma and healthy blood donor sera.
    reference_section_type: ABSTRACT
  - reference_id: PMID:25122923
    supporting_text: >-
      A previously indicated exosomal TXNDC16 secretion could not be confirmed in
      HEK293 cells.
    reference_section_type: ABSTRACT
proposed_new_terms: []
references:
- id: GO_REF:0000044
  title: Gene Ontology annotation based on UniProtKB/Swiss-Prot Subcellular Location
    vocabulary mapping, accompanied by conservative changes to GO terms applied by
    UniProt
  findings: []
- id: PMID:19199708
  title: Proteomic analysis of human parotid gland exosomes by multidimensional protein
    identification technology (MudPIT).
  findings: []
  reference_review:
    relevance: LOW
    correctness: VERIFIED
    review_notes: >-
      High-throughput exosome proteomics; source of the extracellular exosome annotation, which a
      later study could not reproduce. Not informative for TXNDC16's molecular function.
- id: PMID:21359175
  title: Identification of the PDI-family member ERp90 as an interaction partner of
    ERFAD.
  findings:
  - statement: >-
      ERp90/TXNDC16 is a soluble ER-luminal glycoprotein with about five potential thioredoxin
      domains, none of which contain a canonical CXXC active-site motif; it directly interacts with
      the ERAD flavoprotein ERFAD (FOXRED2), suggesting a role in substrate recruitment/delivery to
      the ERAD retrotranslocation machinery.
    reference_section_type: ABSTRACT
  reference_review:
    relevance: HIGH
    correctness: VERIFIED
    review_notes: >-
      Full-text cached; the defining functional characterization of TXNDC16/ERp90, establishing ER-
      lumen localization, the absence of a canonical CXXC motif, and the ERFAD/ERAD interaction.
- id: PMID:25122923
  title: Secretion and immunogenicity of the meningioma-associated antigen TXNDC16.
  findings:
  - statement: >-
      TXNDC16 is an ER-luminal glycoprotein that is secreted from human cell lines because its KDEL
      ER-retrieval motif is masked and non-functional; it is a meningioma-associated antigen, and a
      previously reported exosomal secretion could not be confirmed.
    reference_section_type: ABSTRACT
  full_text_unavailable: true
  reference_review:
    relevance: MEDIUM
    correctness: VERIFIED
    review_notes: >-
      Cached entry is abstract-only; supports the ER-lumen localization, the masked-KDEL-driven
      secretion, and casts doubt on the exosomal localization.
- id: PMID:32971745
  title: Oxidoreductases in Glycoprotein Glycosylation, Folding, and ERAD.
  findings:
  - statement: >-
      Authoritative review that classifies ERp90/TXNDC16 as a non-catalytic PDI-family
      member whose thioredoxin-like domains carry non-canonical motifs (CX8C, CX9C, CX6C)
      rather than active CXXC, and places it within the ERAD retrotranslocation network
      alongside factors such as OS-9 and SEL1L.
    reference_section_type: LITERATURE_REVIEW
  reference_review:
    relevance: MEDIUM
    correctness: VERIFIED
    review_notes: >-
      PubMed-verified (PMID:32971745, DOI:10.3390/cells9092138). Review-level synthesis that
      corroborates the primary finding (PMID:21359175) that TXNDC16/ERp90 lacks a canonical CXXC
      and is likely non-catalytic, and frames it within ERAD glycoprotein quality control. The
      specific non-canonical motif assignments and OS-9/SEL1L associations are review/family-level
      inferences, not gene-specific primary data, so no new annotations are derived from them.
- id: PMID:38673779
  title: Innovation in Non-Invasive Diagnosis and Disease Monitoring for Meningiomas.
  findings:
  - statement: >-
      Review of meningioma liquid-biopsy approaches that summarizes prior work on TXNDC16 as a
      meningioma-associated antigen, noting a five-epitope autoantibody panel discriminating
      meningioma from healthy sera with ~90% sensitivity and ~83.7% specificity as a
      proof-of-concept serology biomarker.
    reference_section_type: LITERATURE_REVIEW
  reference_review:
    relevance: LOW
    correctness: VERIFIED
    review_notes: >-
      PubMed-verified (PMID:38673779, DOI:10.3390/ijms25084195). Secondary review that restates the
      Harz 2014 (PMID:25122923) TXNDC16 meningioma autoantibody/biomarker findings; contextual
      disease/biomarker relevance only, not new mechanistic evidence for the gene's molecular
      function.
- id: file:human/TXNDC16/TXNDC16-uniprot.txt
  title: UniProt entry Q9P2K2 (TXD16_HUMAN), Thioredoxin domain-containing protein 16
  findings:
  - statement: >-
      Large PDI-family ER-luminal glycoprotein (ERp90) with a thioredoxin domain and a masked,
      non-functional KDEL ER-retention motif; interacts with FOXRED2 (ERFAD); secreted.
    reference_section_type: OTHER
suggested_questions:
- question: >-
    Does TXNDC16/ERp90 possess any thiol-disulfide redox activity despite lacking a canonical CXXC
    motif, using its other conserved cysteines, or is it a purely non-catalytic scaffold/adapter?
- question: >-
    Is the proposed ERAD substrate-recruitment/delivery role (via ERFAD/FOXRED2) borne out by
    identifying endogenous ERAD substrates whose degradation depends on TXNDC16?
suggested_experiments:
- description: >-
    Knock out TXNDC16 in human cells and assay the degradation kinetics of model ERAD substrates,
    with and without ERFAD/FOXRED2, to test the proposed substrate-delivery function.
- description: >-
    Perform in vitro redox assays (e.g., insulin turbidimetric reduction, RNase refolding) with
    purified TXNDC16 and active-site cysteine mutants to determine whether it has any catalytic
    oxidoreductase activity in the absence of a canonical CXXC motif.

TXNDC16

Gene Description

Existing Annotations Review

Core Functions

ER-luminal PDI-family glycoprotein that lacks a canonical CXXC redox motif and acts as a direct interaction partner of the ERAD flavoprotein ERFAD (FOXRED2), proposed to function in recruitment or delivery of substrates to the ERAD retrotranslocation machinery.

References

Suggested Questions for Experts

Suggested Experiments

Knowledge Gaps

Deep Research

Falcon

Research report: Human TXNDC16 (ERp90; UniProt Q9P2K2)—functional annotation, localization, pathways, and translational relevance

0) Target verification (mandatory)

1) Key concepts and definitions (current understanding)

1.1 Thioredoxin-like / PDI-family-like proteins in the ER

1.2 ER targeting and retention/retrieval signals

2) Molecular identity, domain architecture, and biochemical function

2.1 Protein identity and size

2.2 Domain/motif-level functional inference: “thioredoxin-like but non-catalytic”

3) Subcellular localization and trafficking

3.1 ER localization (experimental evidence)

3.2 ER retention vs secretion (unusual behavior)

4) Pathways and interaction partners (ERAD-focused)

4.1 ERAD/retrotranslocation complexes

4.2 Expert framing within the “ER redoxome”

5) Recent developments and latest research (prioritizing 2023–2024)

5.1 2024 expert review: TXNDC16 in non-invasive meningioma biomarker development

5.2 2023–2024 TXNDC16 mechanistic biology: limited direct primary data retrieved

6) Current applications and real-world implementations

6.1 Potential clinical application: serology-based meningioma liquid biopsy (not yet clinically validated)

6.2 Systems/proteostasis application: inclusion in ERAD network models

7) Expert opinions and analysis (authoritative synthesis)

8) Statistics and quantitative data from studies

8.1 Meningioma discrimination performance (primary data)

8.2 Database-level disease association scores (interpret with caution)

9) Limitations and evidence gaps (important for functional annotation)

Summary table of evidence

Key sources (with dates and URLs)

Artifacts

Citations

TXNDC16/ERp90: Catalytic PDI-Family Oxidoreductase or Non-Catalytic ER-Luminal Scaffold?

TXNDC16/ERp90: Catalytic PDI-Family Oxidoreductase or Non-Catalytic ER-Luminal Scaffold?

Summary

Key Findings

Finding 1: TXNDC16 Completely Lacks Canonical CXXC Active-Site Motifs

Finding 2: The C449–C456 Disulfide Is Structural, Not Catalytic

Finding 3: TXNDC16 Co-Immunoprecipitates with ERFAD, an ERAD-Pathway Flavoprotein

Finding 4: No In Vitro Enzymatic Assay Has Been Published for TXNDC16

Finding 5: GO Annotation Supports Only Protein Binding

Mechanistic Model: TXNDC16 as an ERAD Substrate Adaptor

Key Features of This Model

Distinguishing Direct Catalytic Evidence from Indirect Inference

Evidence Base: Key Literature

Primary Literature on TXNDC16

ERFAD and ERAD Pathway Literature

CXXC Motif and PDI Catalysis Literature

Contextual PDI-Family Reviews

Limitations and Knowledge Gaps

What We Do Not Know

Caveats

Proposed Follow-up Experiments

Priority 1: Definitive Enzymatic Testing

Priority 2: Redox-State Characterization

Priority 3: Substrate and Complex Characterization

Priority 4: Structural Biology

Defensible Molecular Function Annotation

References

OpenScientist prompt: TXNDC16/ERp90 redox activity versus non-catalytic scaffold function

OpenScientist prompt: TXNDC16/ERp90 redox activity versus non-catalytic scaffold function

📚 Additional Documentation

Notes

TXNDC16 (Q9P2K2) review notes

Identity

Key functional evidence

PMID:21359175 (Riemer et al. 2011, "Identification of the PDI-family member ERp90 as an interaction partner of ERFAD") — full text cached

PMID:25122923 (Harz et al. 2014, "Secretion and immunogenicity of the meningioma-associated antigen TXNDC16") — abstract only cached

PMID:19199708 (parotid gland exosome MudPIT proteomics) — HDA extracellular exosome

Redox/catalytic status

GOA assessment

Core function summary